Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma

INTRODUCTION: B7-H3 is a potential target for pediatric cancers, including neuroblastoma (NB). Vobramitamab duocarmazine (also referred to as MGC018 and herein referred to as vobra duo) is an investigational duocarmycin-based antibody-drug conjugate (ADC) directed against the B7-H3 antigen. It is co...

Descripción completa

Detalles Bibliográficos
Autores principales: Brignole, Chiara, Calarco, Enzo, Bensa, Veronica, Giusto, Elena, Perri, Patrizia, Ciampi, Eleonora, Corrias, Maria Valeria, Astigiano, Simonetta, Cilli, Michele, Loo, Derik, Bonvini, Ezio, Pastorino, Fabio, Ponzoni, Mirco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546160/
https://www.ncbi.nlm.nih.gov/pubmed/37775116
http://dx.doi.org/10.1136/jitc-2023-007174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546160/
https://www.ncbi.nlm.nih.gov/pubmed/37775116
http://dx.doi.org/10.1136/jitc-2023-007174

Ejemplares similares